Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dapsone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promising COVID-19 Therapeutic Drug to start Phase 3 Clinical Trial in the United States
Details : PULM-001 data shown to prevent and treat acute respiratory distress syndrome due to SARS-CoV-2 infection and reduce mortality from 40% to 0% in a small, randomized clinical trial.
Product Name : PULM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2021
Lead Product(s) : Dapsone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapsone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Mcgill University Health Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase III Clinical Trial is sponsored by the Research Institute of the McGill University Health Centre (RI-MUHC) and will be conducted in seven centres in Canada and the United States as soon as the necessary funding has been secured.
Product Name : PULM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2020
Lead Product(s) : Dapsone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Mcgill University Health Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
